High-dose therapy with stem cell rescue for pediatric solid tumors: rationale and results.
Metastatic and recurrent pediatric solid tumors usually respond to chemotherapy but are likely to recur. Because of steep dose-response relationships, HDT requiring hematopoietic rescue may improve outcome. This strategy has recently been shown to be effective for metastatic neuroblastoma. Metastatic Ewing's sarcoma appears to be a closely analogous situation, and promising phase II studies suggest that a definitive trial of efficacy would be appropriate. Phase I or II trials remain appropriate and are needed to define further the efficacy of HDT for most other poor prognosis pediatric solid tumors.
Chen
A R
AR
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-5001, USA. archen@jhmi.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D012516:Osteosarcoma / Q000628:therapy; D011379:Prognosis; D012208:Rhabdomyosarcoma / Q000628:therapy; D012509:Sarcoma / Q000401:mortality / Q000628:therapy*; D012512:Sarcoma, Ewing / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome; D009396:Wilms Tumor / Q000401:mortality / Q000628:therapy*